Clinical trial · Interventional
Randomized Control Trial (RCT) of Transarterial Chemoembolization (TACE) Versus TACE and Oral Drug Therapy in the Treatment of Unresectable Hepatocellular Carcinoma
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Background Hepatocellular carcinoma, a malignant tumor of liver is one of the most common cancers worldwide. All India Institute Of Medical Sciences (AIIMS) being a tertiary care hospital receives about two to three cases of Hepatocellular carcinoma (HCC) each day in our Gastroenterology out patient department. Most of these patients present late when the disease is already advanced and no curative therapies can be offered. At this stage, palliative therapy forms the mainstay of treatment. This includes TACE or Oral chemotherapy. Whether oral chemotherapy administered along with TACE potentiates the effect and further prolongs survival, needs to be ascertained. No studies of this kind are available. This prospective study is therefore designed to address this issue.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hepatocellular Carcinoma | Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| TACE | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- 1
- description
- Transarterial Chemoembolisation
- interventionNames
- Procedure: TACE
- type
- ACTIVE_COMPARATOR
- label
- 2
- description
- TACE Plus oral chemotherapy
- interventionNames
- Procedure: TACE
Primary outcomes (1)
- measure
- Survival rate- calculated from the start of TACE
Secondary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 12 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * Patients above 12 years of age with performance status (PST)score of 0-2 * Unresectable HCC with underlying Child's A/B cirrhosis * Normal Main portal vein and its branches * Normal Inferior vena cava * No history of drug allergy * Informed written consent of patient. * Less than 50% involvement of liver by HCC Exclusion Criteria: * Unresectable HCC with underlying Child's C cirrhosis * Performance status 3-5 * Extrahepatic disease * Vascular involvement * Co-morbid illness like coronary artery disease, congestive heart failure, chronic renal failure etc * Previous history of encephalopathy/ upper gastrointestinal bleed in the last six months * HCC in a female of child bearing age
References
Publications (0)
Data not yet available